Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aeglea Biotherapeutics
Biotech
Aeglea sells off rare disease asset to Immedica for $15M
Aeglea has sold off its rare metabolic disease asset to Immedica Pharma for $15 million cash and the chance to make up to $100 million more.
Gabrielle Masson
Jul 27, 2023 11:00am
Guth takes reins of Bayer’s US operations—Chutes & Ladders
Jun 23, 2023 9:30am
Aeglea scoops up Spyre to stay afloat
Jun 22, 2023 10:50am
Aeglea lays off more staff, seeks exit in face of rocky data
Apr 12, 2023 9:35am
Aeglea's layoffs curb spending, but cash crunch still on cards
Mar 3, 2023 7:48am
New CEO will lead Teva at top of new year—Chutes & Ladders
Dec 2, 2022 9:30am
